Hormone Replacement Therapy (HRT)

Overview

Hormone Replacement Therapy (HRT), also widely known as Menopausal Hormone Therapy (MHT), refers to the medical use of hormones, primarily estrogen, with or without a progestogen, to replace the natural decline in ovarian hormone production that occurs during the menopausal transition.^[1] The therapy is intended to alleviate the diverse symptoms caused by falling estrogen levels and, in certain cases, to provide long-term protective benefits for bones and overall health.^[2] Estrogen is the principal hormone used, while progesterone or synthetic progestins are added in women with an intact uterus to prevent endometrial overgrowth and reduce the risk of endometrial cancer.^[3][4] For women who have undergone a hysterectomy, estrogen alone may be sufficient.^[5]

The main reason HRT is prescribed is to relieve vasomotor symptoms such as hot flashes and night sweats, which are the most common and distressing complaints during menopause.^[6] Beyond vasomotor relief, HRT improves sleep, mood, and sexual function by addressing symptoms of genitourinary syndrome of menopause (GSM), including vaginal dryness, painful intercourse, and urinary frequency.^[7] In addition, systemic estrogen therapy helps to maintain bone density and reduce fracture risk, making it especially important for women who enter menopause early or who are at high risk for osteoporosis.^[8][9] For many women, these benefits contribute to significant improvements in quality of life, work productivity, and psychosocial well-being.

Is Hormone Replacement Therapy Right for You?

Hormone Replacement Therapy (HRT) can be a game-changer for many women going through menopause, providing relief from common symptoms like hot flashes, night sweats, vaginal dryness, and urinary issues. It is especially beneficial for women who are experiencing moderate to severe vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), or osteoporosis risk due to early or surgical menopause. For those with premature ovarian insufficiency (POI), starting HRT as soon as possible can prevent long-term health risks such as bone loss, heart disease, and cognitive decline.^[10] However, while HRT offers significant benefits, it is not for everyone. Women with a history of hormone-sensitive cancers, such as breast or endometrial cancer, should avoid systemic estrogen therapy, though low-dose vaginal estrogen might be considered in some cases under specialist guidance.^[11][12] Unexplained vaginal bleeding should always be investigated before starting HRT, as it may signal underlying conditions such as endometrial hyperplasia. Women with a history of blood clots (VTE), stroke, or liver disease should be cautious, especially with oral estrogen, as it can increase clotting risks.^[13] In such cases, transdermal estradiol is a safer option. Lastly, women with uncontrolled hypertension or high cardiovascular risk should approach HRT with caution, as estrogen may exacerbate these conditions. Ultimately, HRT is an individualized therapy, and careful evaluation of benefits versus risks is essential to determine if it’s the right choice.

Benefits of Hormone Replacement Therapy

The primary goal of HRT is to relieve symptoms caused by declining estrogen levels during menopause. Decades of clinical trials and observational studies have shown that HRT is the most effective treatment for vasomotor symptoms such as hot flashes and night sweats, while also offering additional advantages for bone health, vaginal and urinary function, and quality of life.^[14][15] These benefits are most significant for women who begin therapy soon after menopause, particularly those experiencing premature or early menopause.

Benefit	What It Does	Evidence & Clinical Significance
Relief of Vasomotor Symptoms	Reduces hot flashes and night sweats by up to 70–80% in most women.	RCTs and meta-analyses confirm HRT is the most effective treatment for vasomotor symptoms, often working within weeks.[16] Improves comfort, work performance, and daily activities.
Improved Sleep & Mood	Better sleep quality by reducing night sweats; may help with mood swings, anxiety, and “brain fog.”	Women often report fewer awakenings, improved concentration, and enhanced emotional stability. Indirect benefits on cognition through sleep improvement are recognized.[17]
Vaginal & Urinary Health (GSM)	Restores vaginal tissue thickness, elasticity, and lubrication; reduces painful intercourse and urinary frequency/urgency.	Local vaginal estrogen and systemic estrogen are first-line for GSM. Studies show long-term safety of low-dose vaginal preparations, with minimal systemic absorption.[18][19]
Bone Density & Fracture Prevention	Prevents postmenopausal bone loss and reduces vertebral, hip, and other fractures while on therapy.	WHI and other trials show a 30–40% reduction in hip and vertebral fractures. Particularly important for women with early menopause or high osteoporosis risk.[20][21]

Risks of HRT

While HRT provides meaningful relief and preventive benefits, it is not without risks. The safety profile depends on factors such as the type of hormones used, the route of administration, the woman’s age at initiation, and the duration of therapy. The risks outlined below highlight potential complications but also show how many of these can be minimized through careful patient selection, use of transdermal routes, and appropriate progestogen protection.

Risk	Description	Factors that Influence Risk
Breast Cancer	Combined estrogen–progestogen therapy increases risk modestly with duration (>5 years).[22][23] Estrogen-only therapy (in women without a uterus) shows little to no increase in most analyses.[24]	Duration of use, type of progestogen (micronized progesterone appears safer than some synthetic progestins), and baseline risk factors (family history, mammographic density).[25]
Deep Vein Thrombosis (DVT)	Oral estrogen increases risk of deep vein thrombosis (DVT) and pulmonary embolism.[26]	Route matters: transdermal estradiol has little to no added VTE risk at standard doses, making it preferable for women with risk factors (obesity, thrombophilia, immobility).[27][28]
Stroke	Oral HRT slightly increases ischemic stroke risk, especially in older women.	Dose and route matter: low-dose transdermal estrogen shows no excess risk, while high-dose transdermal (>50 µg/day) and oral forms are riskier.[29][30]
Heart Disease	Not recommended for cardiovascular prevention. Timing hypothesis: safer when started <60 years or within 10 of menopause; riskier if begun later.[31]	Baseline cardiovascular risk (hypertension, diabetes, smoking, prior events) should guide decisions.[32]
Endometrial Cancer	Estrogen-only therapy in women with a uterus increases endometrial hyperplasia/cancer risk.[33]	Adding a progestogen (cyclic or continuous) or an LNG-IUS eliminates this risk.[34]
Gallbladder Disease	Oral estrogen increases risk of gallstones and gallbladder surgery.[35]	Transdermal estrogen bypasses the liver and carries lower risk.[36]

Types and Routes of Therapy

Hormone Replacement Therapy (HRT) can be tailored to the individual’s needs based on factors such as whether they have a uterus, the severity of their symptoms, and their risk profile.^[37] There are different types and routes of administration, each with distinct benefits and considerations. Understanding these options helps to ensure optimal therapy selection and minimizes risks.

Estrogen-only therapy

This type of HRT is typically prescribed for women who have had a hysterectomy (removal of the uterus).^[38] Without a uterus, there is no need for progestogen to protect against endometrial hyperplasia (excessive thickening of the uterine lining). Estrogen-only therapy is effective in relieving vasomotor symptoms (hot flashes, night sweats) and preventing bone loss.^[39]

Combined estrogen and progestogen therapy

Combined HRT is used for women who still have a uterus. Progestogen is necessary to protect the endometrium from overgrowth caused by estrogen, which can increase the risk of endometrial cancer.^[40] This form of therapy is commonly used for treating both vasomotor symptoms and genitourinary symptoms (vaginal dryness, painful intercourse).

Local therapies

Local therapies (such as vaginal estrogen, DHEA, and ospemifene) are primarily used to treat genitourinary syndrome of menopause (GSM), including vaginal dryness, discomfort during intercourse, and urinary issues.^[41] These treatments are usually prescribed in low doses and are absorbed directly into the vaginal tissues with minimal systemic effects. Vaginal estrogen is the most commonly used, but DHEA (dehydroepiandrosterone) and ospemifene (a selective estrogen receptor modulator) can also be effective for managing GSM.^[42]

Routes of Administration

HRT can be administered in several ways, with oral tablets being the most traditional and convenient method. However, oral estrogen is processed through the liver, which can increase the risk of blood clots (VTE) in some women. Transdermal therapy (patches, gels, sprays) delivers estrogen directly into the bloodstream through the skin, bypassing the liver, and thereby reduces clot risk, making it a preferred option for women with higher cardiovascular risks.^[43] Vaginal options, such as creams, tablets, and the vaginal ring, are typically used for local symptom relief in genitourinary syndrome of menopause (GSM), including vaginal dryness and discomfort.^[44] Some vaginal products, like the vaginal ring, can also deliver systemic estrogen for broader symptom management with minimal systemic effects, making them ideal for long-term use in women who primarily need localized therapy but may also benefit from overall symptom relief.^[45]

Alternatives to HRT

HRT remains the most effective treatment for managing many menopausal symptoms, but it is not the only option. For some women, particularly those who cannot or prefer not to take hormones, there are non-hormonal treatments available. These options can be effective in managing symptoms like hot flashes, mood disturbances, and vaginal dryness. They provide viable alternatives that may suit specific health profiles and personal preferences.

Alternatives	Description	Benefits
SSRIs/SNRIs	These are antidepressants that can help manage vasomotor symptoms (VMS) like hot flashes by influencing serotonin levels in the brain.[46]	Effective for reducing hot flashes and improving mood. Helps with anxiety and depression, which are often associated with menopause.[47]
Gabapentin	Originally developed for treating seizures, gabapentin is used off-label for hot flashes, especially in women who cannot take HRT. It works by stabilizing nerve activity.[48]	Effective for hot flashes, especially for those with neuropathic pain or insomnia. It may also reduce night sweats.[49]
Fezolinetant	A non-hormonal drug that blocks the NK3 receptor, which helps regulate the body’s temperature control mechanism.[50]	Reduces hot flashes significantly in clinical trials without the use of hormones.[51][52]
Cognitive Behavioral Therapy (CBT)	A psychological intervention designed to help women manage stress, mood swings, sleep disturbances, and anxiety associated with menopause.[53]	Helps improve overall mental well-being, reduces stress, and improves sleep quality. CBT is especially relevant for breast cancer survivors in whom HRT is contraindicated.[54]
Lifestyle Changes	Changes such as regular exercise, healthy eating, avoiding triggers (caffeine, alcohol, smoking), and sleep hygiene can significantly reduce hot flashes and improve menopause symptoms.[55]	Regular physical activity reduces VMS, improves mood, reduces bone loss, improves sleep quality, and helps manage weight gain during menopause.[56]
Vaginal DHEA (Dehydroepiandrosterone)	A non-hormonal treatment that is converted into estrogen and androgen within vaginal tissues. It can help manage symptoms of GSM.[57]	Alleviates vaginal dryness, reduces discomfort during intercourse, and improves vaginal elasticity.[58]
Ospemifene	A selective estrogen receptor modulator (SERM) used to treat moderate-to-severe dyspareunia (painful intercourse) caused by vaginal atrophy associated with menopause.[59]	Treats vaginal dryness and discomfort effectively. It can be an alternative to estrogen in certain women.[60]

FAQs

How long should I stay on HRT?

The duration of HRT is highly individualized and should be based on symptom control, age, and risk assessment. For most women, short-term use (3–5 years) is sufficient to manage menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. However, if symptoms persist beyond this period, many women opt to continue therapy for longer durations, often until the age of 60. The key principle is to use the lowest effective dose for the shortest time necessary to control symptoms. After age 60, the decision to continue HRT should involve careful consideration of potential risks, such as cardiovascular disease, breast cancer, and stroke. Annual evaluations are critical to reassess the benefit-risk ratio and determine whether continued therapy is still appropriate. Some women may decide to taper off HRT gradually, as symptoms improve, while others may use it longer if the benefits (such as improved quality of life and bone health) continue to outweigh the risks. If you choose to stop, regular follow-up with your doctor will help monitor your symptoms and explore other options if needed.

How do I know if I’m a good candidate for HRT?

Ideal candidates for HRT are women who are experiencing significant menopausal symptoms, such as hot flashes, night sweats, vaginal dryness, and mood disturbances, and who do not have contraindications. For women who are in perimenopause or within 10 years of menopause (typically under 60 years of age), HRT can provide excellent symptom relief and help protect against bone loss. Before starting HRT, it’s crucial to undergo a thorough evaluation with your healthcare provider, including a review of your medical history, symptom severity, and risk factors. This includes assessing your cardiovascular health, family history of breast cancer, and any previous thromboembolic events (such as blood clots or stroke). If you have a history of hormone-sensitive cancers, unexplained vaginal bleeding, active liver disease, or uncontrolled hypertension, HRT may not be appropriate. In such cases, your provider will discuss alternative therapies, including non-hormonal options (e.g., SSRIs/SNRIs, gabapentin), vaginal moisturizers, or lifestyle changes to manage symptoms. Ultimately, whether you’re a candidate for HRT depends on your specific needs, preferences, and health profile, and ongoing dialogue with your healthcare provider will help ensure the safest and most effective approach.

Research Feed

Update History

References

1. Hormone Replacement Therapy. [Updated 2024 Oct 6].. Harper-Harrison G, Carlson K, Shanahan MM.. (In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.)
2. Optimizing menopausal hormone therapy: For treatment and prevention, menstrual regulation, and reduction of possible risks.. Ruan, X., & Mueck, A. O. (2022).. (Global Health Journal, 6(2), 61-69.)
3. Adverse endometrial effects during long cycle hormone replacement therapy.. Bjarnason, K., Cerin, Å., Lindgren, R., & Weber, T. (1999).. (Maturitas, 32(3), 161-170.)
4. Progesterone: The ultimate endometrial tumor suppressor.. Yang, S., Thiel, K. W., & Leslie, K. K. (2011).. (Trends in Endocrinology and Metabolism: TEM, 22(4), 145.)
5. Estrogen Therapy. [Updated 2025 Feb 18].. Valdes A, Patel P, Bajaj T.. (In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.)
6. Hormone Replacement Therapy. [Updated 2024 Oct 6].. Harper-Harrison G, Carlson K, Shanahan MM.. (In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.)
7. The 2020 Menopausal Hormone Therapy Guidelines.. Lee, S. R., Cho, M. K., Cho, Y. J., Chun, S., Hong, H., Hwang, K. R., Jeon, H., Joo, J. K., Kim, S. K., Lee, D. O., Lee, Y., Lee, E. S., Song, J. Y., Yi, K. W., Yun, B. H., Shin, H., Chae, H. D., & Kim, T. (2020).. (Journal of Menopausal Medicine, 26(2), 69.)
8. The 2020 Menopausal Hormone Therapy Guidelines.. Lee, S. R., Cho, M. K., Cho, Y. J., Chun, S., Hong, H., Hwang, K. R., Jeon, H., Joo, J. K., Kim, S. K., Lee, D. O., Lee, Y., Lee, E. S., Song, J. Y., Yi, K. W., Yun, B. H., Shin, H., Chae, H. D., & Kim, T. (2020).. (Journal of Menopausal Medicine, 26(2), 69.)
9. Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis.. Na, Z., Wei, W., Xu, Y., Li, D., Yin, B., & Gu, W. (2023).. (Open Life Sciences, 18(1), 20220759.)
10. HRT for women with premature ovarian insufficiency: A comprehensive review.. Webber, L., Anderson, R. A., Davies, M., Janse, F., & Vermeulen, N. (2017).. (Human Reproduction Open, 2017(2), hox007.)
11. Hormone Replacement Therapy. [Updated 2024 Oct 6].. Harper-Harrison G, Carlson K, Shanahan MM.. (In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.)
12. Long-term postmenopausal hormone therapy and endometrial cancer.. Razavi, P., Pike, M. C., Horn-Ross, P. L., Templeman, C., Bernstein, L., & Ursin, G. (2010).. (Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 19(2), 475.)
13. Estrogen Therapy. [Updated 2025 Feb 18].. Valdes A, Patel P, Bajaj T.. (In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.)
14. The 2020 Menopausal Hormone Therapy Guidelines.. Lee, S. R., Cho, M. K., Cho, Y. J., Chun, S., Hong, H., Hwang, K. R., Jeon, H., Joo, J. K., Kim, S. K., Lee, D. O., Lee, Y., Lee, E. S., Song, J. Y., Yi, K. W., Yun, B. H., Shin, H., Chae, H. D., & Kim, T. (2020).. (Journal of Menopausal Medicine, 26(2), 69.)
15. Hormone therapy for first-line management of menopausal symptoms: Practical recommendations.. Palacios, S., Stevenson, J. C., Schaudig, K., Lukasiewicz, M., & Graziottin, A. (2019).. (Women's Health, 15, 1745506519864009.)
16. Vasomotor Symptoms During Menopause: A Practical Guide on Current Treatments and Future Perspectives.. Khan, S. J., Kapoor, E., Faubion, S. S., & Kling, J. M. (2023).. (International Journal of Women's Health, 15, 273.)
17. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.. Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015).. (The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011.)
18. Menopausal hormone therapy and menopausal symptoms.. Al-Safi, Z. A., & Santoro, N. (2014).. (Fertility and Sterility, 101(4), 905-915.)
19. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.. Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015).. (The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011.)
20. Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis.. Na, Z., Wei, W., Xu, Y., Li, D., Yin, B., & Gu, W. (2023).. (Open Life Sciences, 18(1), 20220759.)
21. Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts.. Mehta, J., Kling, J. M., & Manson, J. E. (2021).. (Frontiers in Endocrinology, 12, 564781.)
22. Hormone Replacement Therapy. [Updated 2024 Oct 6].. Harper-Harrison G, Carlson K, Shanahan MM.. (In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.)
23. Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin.. Ross, R. K., Wan, P. C., & Pike, M. C. (2000).. (JNCI: Journal of the National Cancer Institute, 92(4), 328-332.)
24. Estrogens and breast cancer.. Kim, J., & Munster, P. (2025).. (Annals of Oncology, 36(2), 134-148.)
25. Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts.. Mehta, J., Kling, J. M., & Manson, J. E. (2021).. (Frontiers in Endocrinology, 12, 564781.)
26. Estrogen and Thrombosis: A Bench to Bedside Review.. Abou-Ismail, M. Y., Sridhar, D. C., & Nayak, L. (2020).. (Thrombosis Research, 192, 40.)
27. Hormonal therapies and venous thrombosis: Considerations for prevention and management.. LaVasseur, C., Neukam, S., Kartika, T., Bannow, B. S., Shatzel, J., & DeLoughery, T. G. (2022).. (Research and Practice in Thrombosis and Haemostasis, 6(6), e12763.)
28. Effects of transdermal versus oral hormone replacement therapy in postmenopause: A systematic review.. Goldštajn, M. Š., Mikuš, M., Ferrari, F. A., Bosco, M., Uccella, S., Noventa, M., Török, P., Terzic, S., Laganà, A. S., & Garzon, S. (2022).. (Archives of Gynecology and Obstetrics, 307(6), 1727.)
29. Hormone therapy and the risk of stroke: Perspectives ten years after the Women’s Health Initiative trials.. Henderson, V. W., & Lobo, R. A. (2012).. (Climacteric : The Journal of the International Menopause Society, 15(3), 229.)
30. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: A systematic review.. Glisic, M., Shahzad, S., Brown, E., Pellegrino Baena, C., Chadni, M., Chowdhury, R., Franco, O. H., & Muka, T. (2019).. (Human Reproduction Update, 25(2), 257-271.)
31. Estrogen and cardiovascular disease.. Gersh, F., O'Keefe, J. H., Elagizi, A., Lavie, C. J., & Laukkanen, J. A. (2024).. (Progress in Cardiovascular Diseases, 84, 60-67.)
32. Rethinking Menopausal Hormone Therapy: For Whom, What, When and How long?. Cho, L., Kaunitz, A. M., Faubion, S. S., Hayes, S. N., Lau, E. S., Pristera, N., Scott, N., Shifren, J. L., Shufelt, C. L., Stuenkel, C. A., Lindley, K. J., & Committee, W. (2023).. (Circulation, 147(7), 597.)
33. Long-term postmenopausal hormone therapy and endometrial cancer.. Razavi, P., Pike, M. C., Horn-Ross, P. L., Templeman, C., Bernstein, L., & Ursin, G. (2010).. (Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 19(2), 475.)
34. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia.. Furness, S., Roberts, H., Marjoribanks, J., & Lethaby, A. (2012).. (The Cochrane Database of Systematic Reviews, 2012(8), CD000402.)
35. Menopausal hormone therapy increases the risk of gallstones: Health Insurance Database in South Korea (HISK)-based cohort study.. Yuk, S., & Park, J. Y. (2023).. (PLOS ONE, 18(12), e0294356.)
36. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: Prospective cohort study.. Liu, B., Beral, V., Balkwill, A., Green, J., Sweetland, S., & Reeves, G. (2008).. (The BMJ, 337, a386.)
37. Hormone Replacement Therapy. [Updated 2024 Oct 6].. Harper-Harrison G, Carlson K, Shanahan MM.. (In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.)
38. ESTROGEN-ONLY MENOPAUSAL THERAPY.. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.. (Pharmaceuticals. Lyon (FR): International Agency for Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100A.))
39. Management of Menopausal Symptoms.. Practice Bulletin No. 141:. (Obstetrics & Gynecology 123(1):p 202-216, January 2014.)
40. Hormone replacement therapy for women previously treated for endometrial cancer.. Edey, K. A., Rundle, S., & Hickey, M. (2018).. (The Cochrane Database of Systematic Reviews, 2018(5), CD008830.)
41. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.. The North American Menopause Society. (Menopause 27(9):p 976-992, September 2020.)
42. A systematic review of randomised clinical trials – The safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors.. Hussain, I., & Talaulikar, V. S. (2023).. (Post Reproductive Health, 29(4), 222.)
43. Hormonal therapies and venous thrombosis: Considerations for prevention and management.. LaVasseur, C., Neukam, S., Kartika, T., Bannow, B. S., Shatzel, J., & DeLoughery, T. G. (2022).. (Research and Practice in Thrombosis and Haemostasis, 6(6), e12763.)
44. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.. The North American Menopause Society. (Menopause 27(9):p 976-992, September 2020.)
45. Intravaginal Drug Delivery Systems to Treat the Genitourinary Syndrome of Menopause: Towards the Design of Safe and Efficacious Estrogen-loaded Prototypes.. Abdelgader, A., Govender, M., Kumar, P., & Choonara, Y. E. (2023).. (Journal of Pharmaceutical Sciences, 112(6), 1566-1585.)
46. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women.. Stubbs, C., Mattingly, L., Crawford, S. A., Wickersham, E. A., Brockhaus, J. L., & McCarthy, L. H. (2017).. (The Journal of the Oklahoma State Medical Association, 110(5), 272.)
47. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women.. Stubbs, C., Mattingly, L., Crawford, S. A., Wickersham, E. A., Brockhaus, J. L., & McCarthy, L. H. (2017).. (The Journal of the Oklahoma State Medical Association, 110(5), 272.)
48. Comparison of Gabapentin with Estrogen for treatment of hot flashes in post-menopausal women.. Allameh, Z., Rouholamin, S., & Valaie, S. (2013).. (Journal of Research in Pharmacy Practice, 2(2), 64.)
49. Use of Gabapentin for the Management of Natural or Surgical Menopausal Hot Flashes.. Hayes LP, Carroll DG, Kelley KW.. (Annals of Pharmacotherapy. 2011;45(3):388-394.)
50. Veozah (Fezolinetant): A Promising Non‐Hormonal Treatment for Vasomotor Symptoms in Menopause. Shaukat, A., Mujeeb, A., Shahnoor, S., Nasser, N., & Khan, A. M. (2023).. (Health Science Reports, 6(10), e1610.)
51. Veozah (Fezolinetant): A Promising Non‐Hormonal Treatment for Vasomotor Symptoms in Menopause. Shaukat, A., Mujeeb, A., Shahnoor, S., Nasser, N., & Khan, A. M. (2023).. (Health Science Reports, 6(10), e1610.)
52. Fezolinetant - a potential alternative to hormone replacement therapy for menopausal women.. Mehmood, H., Komal Zulfiqar, & Ahsanat Fatima. (2024).. (Journal of the Pakistan Medical Association, 74(10), 1919–1919.)
53. Mindfulness, cognitive behavioural and behaviour‐based therapy for natural and treatment‐induced menopausal symptoms: A systematic review and meta‐analysis.. Stuursma, A., Schroevers, M., & Mourits, M. (2018).. (Bjog, 126(3), 330.)
54. Mindfulness, cognitive behavioural and behaviour‐based therapy for natural and treatment‐induced menopausal symptoms: A systematic review and meta‐analysis.. Stuursma, A., Schroevers, M., & Mourits, M. (2018).. (Bjog, 126(3), 330.)
55. The Importance of Nutrition in Menopause and Perimenopause—A Review.. Erdélyi, A., Pálfi, E., Tűű, L., Nas, K., Szűcs, Z., Török, M., Jakab, A., & Várbíró, S. (2023).. (Nutrients, 16(1), 27.)
56. High Physical Activity Level May Reduce Menopausal Symptoms.. Dąbrowska-Galas, M., Dąbrowska, J., Ptaszkowski, K., & Plinta, R. (2019).. (Medicina, 55(8), 466.)
57. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).. Barton, D. L., Shuster, L. T., Dockter, T., Atherton, P. J., Thielen, J., Birrell, S. N., Sood, R., Griffin, P., Terstriep, S. A., Mattar, B., Lafky, J. M., & Loprinzi, C. L. (2017).. (Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 26(4), 1335.)
58. Vaginal DHEA to treat menopause related atrophy: A review of the evidence.. Panjari, M., & Davis, S. R. (2011).. (Maturitas, 70(1), 22-25.)
59. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.. Portman, David J. MD1; Bachmann, Gloria A. MD2; Simon, James A. MD,3 and the Ospemifene Study Group.. (Menopause 20(6):p 623-630, June 2013.)
60. Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause.. Archer DF, Simon JA, Portman DJ, Goldstein SR, Goldstein I.. (Expert Rev Endocrinol Metab. 2019 Sep;14(5):301-314.)